JOP20130186B1 - تنقية الجزيئات الشبيهة بالفيروسات - Google Patents

تنقية الجزيئات الشبيهة بالفيروسات

Info

Publication number
JOP20130186B1
JOP20130186B1 JOP/2013/0186A JOP20130186A JOP20130186B1 JO P20130186 B1 JOP20130186 B1 JO P20130186B1 JO P20130186 A JOP20130186 A JO P20130186A JO P20130186 B1 JOP20130186 B1 JO P20130186B1
Authority
JO
Jordan
Prior art keywords
particles
virus
purification
andnbsp
methods
Prior art date
Application number
JOP/2013/0186A
Other languages
English (en)
Inventor
Taylor Ross
Original Assignee
Takeda Vaccines Montana Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Vaccines Montana Inc filed Critical Takeda Vaccines Montana Inc
Application granted granted Critical
Publication of JOP20130186B1 publication Critical patent/JOP20130186B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/16011—Caliciviridae
    • C12N2770/16051—Methods of production or purification of viral material

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Analytical Chemistry (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

يتعلق الاختراع الحالي بطرق تنقية جسيمات تشبه الفيروس (VLPs) والتي تكون خالية الى حد كبير من ملوثات عملية وعوامل معدية. تشتمل الطرق، على سبيل المثال، على معالجة ذات رقم هيدروجيني منخفض أثناء الحصاد و/أو التخميد بواسطة مذيب و/أو منظف أثناء احتجاز VLP.
JOP/2013/0186A 2012-06-22 2013-06-19 تنقية الجزيئات الشبيهة بالفيروسات JOP20130186B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261663218P 2012-06-22 2012-06-22
US201361794086P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
JOP20130186B1 true JOP20130186B1 (ar) 2021-08-17

Family

ID=49769461

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2013/0186A JOP20130186B1 (ar) 2012-06-22 2013-06-19 تنقية الجزيئات الشبيهة بالفيروسات

Country Status (15)

Country Link
US (3) US10167320B2 (ar)
EP (1) EP2864478B1 (ar)
JP (1) JP6553509B2 (ar)
KR (1) KR102110876B1 (ar)
CN (2) CN114085273B (ar)
AR (1) AR091538A1 (ar)
AU (1) AU2013277959B2 (ar)
CA (1) CA2879815A1 (ar)
IN (1) IN2015DN00089A (ar)
JO (1) JOP20130186B1 (ar)
MX (1) MX366234B (ar)
SG (2) SG11201408459VA (ar)
TW (1) TWI647310B (ar)
UY (1) UY34875A (ar)
WO (1) WO2013192604A1 (ar)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2577833T3 (es) 2006-09-29 2016-07-19 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
SG10201601660YA (en) 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
EP3299030B1 (en) 2011-07-11 2022-06-08 Takeda Vaccines, Inc. Parenteral norovirus vaccine formulations
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
CN105339495A (zh) * 2013-07-11 2016-02-17 宝生物工程株式会社 制备无包膜病毒的方法
AU2014329403B2 (en) 2013-10-03 2020-10-08 Takeda Vaccines, Inc. Methods of detection and removal of rhabdoviruses from cell lines
CN103981084B (zh) * 2014-05-29 2015-11-18 黑龙江省科学院微生物研究所 水中病毒分离提取装置及水中札幌病毒的提取方法
CN107109374B (zh) 2015-01-09 2021-04-06 宝生物工程株式会社 用于生产无包膜病毒颗粒的方法
US10920288B2 (en) 2015-01-16 2021-02-16 Takeda Vaccines, Inc. Detection of particle-contained reverse transcriptase activity
CN105907729B (zh) * 2015-05-05 2019-08-16 广东东阳光药业有限公司 一种制备人乳头瘤病毒l1蛋白类病毒样颗粒的方法
CN107034198B (zh) * 2015-07-15 2021-03-09 长春百克生物科技股份公司 一种嵌合诺如病毒p颗粒及其制备和应用
CA3000329A1 (en) 2015-08-28 2017-03-09 Ology Bioservices, Inc. Norovirus vaccine
CN105779399A (zh) * 2016-03-28 2016-07-20 广西壮族自治区林业科学研究院 一种昆虫杆状病毒纯化方法
GB201614050D0 (en) 2016-08-17 2016-09-28 Glaxosmithkline Ip Dev Ltd Method for purifying viral vectors
KR20190042606A (ko) * 2016-09-01 2019-04-24 다케다 백신즈 인코포레이티드 백신 제조용 바이러스의 제조 방법
EP3420076B1 (en) * 2017-03-06 2024-02-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
EP4382183A3 (en) 2017-03-06 2024-08-21 Guangzhou Realbenefitspot Pharmaceutical Co., Ltd. Methods of producing and characterizing virus vaccine and virus vaccine composition
US11633467B2 (en) 2018-02-15 2023-04-25 Icon Genetics Gmbh Immunogenic composition and vaccine for generating an immune response to norovirus
CN108676781A (zh) * 2018-05-18 2018-10-19 山东信得动物疫苗有限公司 一种重组禽流感病毒的工业化纯化方法
CN108776225A (zh) * 2018-05-23 2018-11-09 中国农业科学院兰州兽医研究所 猪细小病毒VLPs抗体检测试剂盒及其制备方法、应用
US20220152186A1 (en) 2019-03-12 2022-05-19 Icon Genetics Gmbh Norovirus-like particles with improved stability
US12403164B2 (en) 2019-09-30 2025-09-02 Bioverativ Therapeutics Inc. Lentiviral vector formulations
EP4340874A1 (en) 2021-05-21 2024-03-27 Takeda Vaccines, Inc. Solid composition, freeze-drying method and glass vial
EP4362975A4 (en) * 2021-06-28 2025-05-14 VST LLC dba Medgene Labs SAPOVIRUS VACCINES
CN116789773B (zh) * 2022-11-30 2024-02-20 华北制药金坦生物技术股份有限公司 一种胞内表达病毒样颗粒的粗纯方法
WO2025077800A1 (en) * 2023-10-12 2025-04-17 Chengdu Kanghua Biological Products Co., Ltd. Purification of norovirus virus-like particles (vlps)
CN118126202B (zh) * 2024-05-07 2024-07-30 上海瑞宙生物科技有限公司 一种诺如病毒类病毒颗粒及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2833106B2 (ja) 1990-02-21 1998-12-09 株式会社島津製作所 液体クロマトグラフ
WO1994026087A2 (en) 1993-05-14 1994-11-24 Connor Kim C O Recombinant protein production and insect cell culture and process
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
AR004464A1 (es) 1994-11-14 1998-12-16 Merck Sharp & Dohme Un metodo para producir una proteina de capside de papilomavirus
JP3316325B2 (ja) * 1994-12-20 2002-08-19 富士シリシア化学株式会社 ビール安定化処理用シリカゲル及びその製造方法並びにビールの安定化処理方法
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CA2269097C (en) 1996-11-08 2007-01-09 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Synthesis and purification of hepatitis c virus-like particles
CA2302545C (en) 1997-09-05 2012-04-03 Medimmune, Inc. In vitro method for disassembly/reassembly of papillomavirus virus-like particles (vlps)
DE19823814A1 (de) 1998-05-27 1999-12-02 Octapharma Ag Ziegelbruecke Verfahren zur Trennung und/oder Isolierung von Plasmaproteinen mit annularer Chromatographie
PL347472A1 (en) 1998-08-14 2002-04-08 Merck & Co Inc Process for purifying human papillomavirus virus-like particles
KR20010093290A (ko) * 1999-02-05 2001-10-27 폴락 돈나 엘. 사람 파필로마바이러스 백신 제제
US6349843B1 (en) 1999-04-01 2002-02-26 The Vollrath Company Llc Pan removal ramp
EP1186890B1 (en) 1999-06-22 2013-01-02 Japan as Represented by Director-General of National Institute of Infectious Diseases Srsv detection kit
DE10012732A1 (de) 2000-03-18 2001-09-20 Aventis Behring Gmbh Thrombin-Zubereitungen und Verfahren zu ihrer Herstellung
JP2003066021A (ja) 2001-08-28 2003-03-05 Hiroshi Shionoya 連続分取液体クロマトグラフィー装置とそれを用いる方法
US7041500B2 (en) 2002-02-14 2006-05-09 Novavax, Inc. Insect cell line
DK1501369T3 (en) 2002-04-26 2015-09-28 Genentech Inc Non-affinity purification of proteins
EP1585964A4 (en) 2002-08-28 2008-07-16 Introgen Therapeutics Inc CHROMATOGRAPHIC METHODS FOR PURIFYING ADENOVIRUSES
US7879338B2 (en) 2003-07-21 2011-02-01 Boyce Thompson Institute For Plant Research Vectors and methods for immunization against norovirus using transgenic plants
US7481997B1 (en) 2004-02-12 2009-01-27 Montana State University Snow mountain virus genome sequence, virus-like particles and methods of use
WO2006138514A2 (en) 2005-06-16 2006-12-28 Children's Hospital Medical Center Novel norovirus particle for use as an antiviral or vaccine
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
AU2006335256B2 (en) 2005-11-22 2012-10-18 Novartis Vaccines And Diagnostics, Inc. Norovirus and sapovirus antigens
EP2275132B1 (en) 2005-12-29 2021-03-03 Boehringer Ingelheim Animal Health USA Inc. Multivalent PCV2 immunogenic compositions and methods of producing them
JP5683811B2 (ja) 2006-07-27 2015-03-11 タケダ ヴァクシーンズ， インコーポレイテッド キメラインフルエンザウイルス様粒子
ES2577833T3 (es) 2006-09-29 2016-07-19 Takeda Vaccines, Inc. Formulaciones de vacuna para norovirus
US8202967B2 (en) 2006-10-27 2012-06-19 Boehringer Ingelheim Vetmedica, Inc. H5 proteins, nucleic acid molecules and vectors encoding for those, and their medicinal use
HUE028605T2 (en) 2007-03-14 2016-12-28 Takeda Vaccines Inc Cleaning virus-like particles
EP2027875A1 (en) * 2007-08-23 2009-02-25 Octapharma AG A Process for Isolation and Purification of a Target Protein free of Prion Protein (PrPSC)
SG10201601660YA (en) * 2007-09-18 2016-04-28 Takeda Vaccines Inc Method of conferring a protective immune response to norovirus
WO2009080781A1 (en) 2007-12-21 2009-07-02 Cytos Biotechnology Ag Process for clarifying cell homogenates
KR101793161B1 (ko) 2008-08-08 2017-11-03 다케다 백신즈 인코포레이티드 강화된 교차 반응성을 가진 복합체 캡시드 아미노산 서열들을 포함하는 바이러스-유사 입자들
AU2009319979B2 (en) 2008-11-03 2016-10-20 Takeda Vaccines, Inc. Improved methods for isolating enveloped virus-based VLPs free of infectious agents
US8945895B2 (en) 2009-07-31 2015-02-03 Baxter International Inc. Methods of purifying recombinant ADAMTS13 and other proteins and compositions thereof
CA2787666A1 (en) 2010-01-21 2011-07-28 Ligocyte Pharmaceuticals, Inc. Targeted heterologous antigen presentation on calicivirus virus-like particles
JP5903101B2 (ja) 2010-09-20 2016-04-13 バイオ−ラッド ラボラトリーズ インコーポレーティッド クロマトグラフィーにおける生成物と複合体形成した夾雑物の分離方法
FI122520B (fi) 2010-10-15 2012-03-15 Vesna Blazevic Noroviruksen kapsidi ja rotaviruksen VP6-proteiini käytettäväksi yhdistelmärokotteena
CN102260651A (zh) 2011-06-24 2011-11-30 华中科技大学同济医学院附属协和医院 一种纯化病毒样颗粒蛋白的方法及其应用
JOP20130186B1 (ar) 2012-06-22 2021-08-17 Takeda Vaccines Montana Inc تنقية الجزيئات الشبيهة بالفيروسات
JP2015015931A (ja) 2013-07-12 2015-01-29 株式会社Ｕｍｎファーマ ウイルス様粒子を含む培養物の製造方法

Also Published As

Publication number Publication date
JP6553509B2 (ja) 2019-07-31
AU2013277959A1 (en) 2015-01-22
AR091538A1 (es) 2015-02-11
US12286456B2 (en) 2025-04-29
EP2864478A1 (en) 2015-04-29
HK1210210A1 (en) 2016-04-15
EP2864478B1 (en) 2020-12-09
US20220213147A1 (en) 2022-07-07
US10167320B2 (en) 2019-01-01
MX2014015842A (es) 2015-09-07
US20190169236A1 (en) 2019-06-06
MX366234B (es) 2019-07-03
TWI647310B (zh) 2019-01-11
TW201406956A (zh) 2014-02-16
CA2879815A1 (en) 2013-12-27
JP2015521628A (ja) 2015-07-30
IN2015DN00089A (ar) 2015-05-29
AU2013277959B2 (en) 2019-05-16
SG11201408459VA (en) 2015-01-29
CN114085273A (zh) 2022-02-25
CN114085273B (zh) 2024-07-12
WO2013192604A1 (en) 2013-12-27
KR102110876B1 (ko) 2020-05-14
KR20150051988A (ko) 2015-05-13
US11091519B2 (en) 2021-08-17
EP2864478A4 (en) 2015-12-02
UY34875A (es) 2013-12-31
US20140004145A1 (en) 2014-01-02
SG10201610753YA (en) 2017-02-27
CN104583393A (zh) 2015-04-29

Similar Documents

Publication Publication Date Title
MX366234B (es) Purificacion de particulas tipo virus.
PH12015501017A1 (en) Alternative uses for hbv assembly effectors
EA201790630A1 (ru) Способы получения рибозидов
PH12017501258A1 (en) Pyrazine compounds for the treatment of infectious diseases
EA201391152A1 (ru) Ингибиторы вируса гепатита с
EA030115B9 (ru) Новые 6-конденсированные гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PH12014502739A1 (en) Macrocyclic inhibitors of flaviviridae viruses
NZ703040A (en) Macrocyclic inhibitors of flaviviridae viruses
EA026667B9 (ru) Фармацевтическая композиция для лечения вируса гепатита с
EA201590384A1 (ru) 6-аминокислота-гетероарилдигидропиримидины для лечения и профилактики инфекции вируса гепатита в
PH12013501683A1 (en) Yeast-based therapeutic for chronic hepatitis b infection
SG11201406407TA (en) Methods for inactivating viruses during a protein purification process
MY161252A (en) Viral inactivation using improved solvent-detergent method
EA201370017A1 (ru) Ингибиторы вируса гепатита с
CL2014000469A1 (es) Compuestos derivados del acido 2-oxo-6-(aril/heteroaril)-1,2-dihidropiridin-3-carboxilico; composicion farmaceutica; tratamiento combinado; y un metodo de tratamiento de una infeccion bacteriana.
EA201270423A1 (ru) Ингибиторы протеазы hcv
PH12013502442A1 (en) Inactivated dengue virus vaccine
PH12013502177A1 (en) Hepatitis c virus inhibitors
EA201692034A1 (ru) Новые макроциклические соединения
ZA201401020B (en) Benzofuran compounds for the treatment of hepatitis c virus infections
BR112017006589A2 (pt) um método de purificação de lignina por sujeição de uma pasta fluida compreendendo lignina para um campo elétrico
WO2012006149A3 (en) Analogs of c5a and methods of using same
IL232393A0 (en) Substituted benzylamine compounds, their use in medicine, and in particular the treatment of hepatitis c virus (hcv) infection
WO2013005042A3 (en) Anti-viral therapy
WO2013026452A9 (en) Method for removing immunosuppresive properties of hiv envelope glycoproteins